Ryan Hogg

Ryan Hogg is a Europe business reporter at Fortune, writing news and features about the region from the company's London bureau. He previously worked as a business reporter at Insider and for the Financial Times. His reporting focuses on topics such as ransomware attacks on software companies, pharmaceutical pricing discrepancies, insider trading cases involving BP employees, and competition between Novo Nordisk and Eli Lilly in the weight loss drug market.

Biography:  https://fortune.com/author/ryan-hogg/

91%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

95%

Examples:

  • The biases found in Ryan's articles are related to the companies and events he reports on, rather than a personal or political stance.

Conflicts of Interest

88%

Examples:

  • Ryan reports on Novo Nordisk twice, which could create a perceived conflict of interest.

Contradictions

88%

Examples:

  • In one article, Ryan reports contradictory information about CDK Global's ransomware attack and the company's plan to pay the ransom. In another article, he mentions conflicting prices for Ozempic in the US and UK.

Deceptions

90%

Examples:

  • In one article, Ryan includes misleading information about the amount of money demanded in a ransomware attack and the impact on London hospitals.

Recent Articles

CDK Cyberattack Disrupts Thousands of North American Car Dealerships: Demand for Millions in Ransom Payments

CDK Cyberattack Disrupts Thousands of North American Car Dealerships: Demand for Millions in Ransom Payments

Broke On: Wednesday, 19 June 2024 A major cyberattack on CDK, a software provider for car dealerships, has caused widespread disruption across North America, affecting over 15,000 retail locations. The hackers are demanding ransom payments and the impacted dealerships face delays in transactions and financing. CDK's parent company, Brookfield Business Partners LP, has not yet commented on the situation.
Novo Nordisk's Diabetes and Weight Loss Drugs: $600 a Month in the US, $59 in Germany - CEO to Testify Before Senate Committee

Novo Nordisk's Diabetes and Weight Loss Drugs: $600 a Month in the US, $59 in Germany - CEO to Testify Before Senate Committee

Broke On: Monday, 17 June 2024 Novo Nordisk, Europe's most valuable company in 2023, faces scrutiny over price discrepancies of diabetes drugs Ozempic and Wegovy in the US. The CEO will testify before the Senate HELP committee regarding these high prices, which are significantly lower in other countries. A study found that Ozempic costs $541 less per month in Germany, while Wegovy costs $727 less in the UK. Critics argue that justifications for these price disparities do not excuse such significant differences.
Former BP Manager's Husband Pleads Guilty to Insider Trading in $1.8 Million Profit Scheme

Former BP Manager's Husband Pleads Guilty to Insider Trading in $1.8 Million Profit Scheme

Broke On: Saturday, 24 February 2024 Tyler Loudon, the husband of a former BP manager, pleaded guilty to insider trading after secretly buying up $1.8 million worth of shares in truck stop service TravelCentres and made a profit of $1.76 million by selling them after BP announced its acquisition for $1.8 billion.

FDA Approves Eli Lilly's Zepbound for Weight Loss

Broke On: Wednesday, 08 November 2023 FDA has approved Eli Lilly's drug tirzepatide, marketed as Zepbound, for weight loss. Zepbound works by activating two naturally produced hormones in the body, slowing the emptying of the stomach and suppressing appetite. The cost for a month's supply of Zepbound is $1,059.87, cheaper than a similar weight-loss drug, Wegovy, priced at $1,349 for a month's supply.